Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584802 | 0.93 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL5585074 | 0.91 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL4003480 | 0.89 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL5591008 | 0.86 | SLC6A9 (0.77) | SLC6A9 | |
| SCHEMBL5584897 | 0.86 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL5584785 | 0.85 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL1689569 | 0.85 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL4134618 | 0.85 | SLC6A9 (0.75) | SLC6A9 | |
| SCHEMBL4424220 | 0.85 | SLC6A9 (0.61) | SLC6A9 | |
| SCHEMBL5585170 | 0.85 | SLC6A9 (0.61) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684759-A4 | 4-PHENYL PIPERDINE SULFONYL GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20070105902-A1 | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105902-A1 | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105902-A1 | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| EP-1684759-A2 | 4-PHENYL PIPERDINE SULFONYL GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005046601-A2 | 4-PHENYL PIPERDINE SULFONYL GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105902-A1 | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.